Relation among the Tests and Comparison of Positivity of Tests for Multi-Drug Resistance in Newly Diagnosed Acute Leukemia.
- Author:
Nan Young LEE
1
;
Hye Gyung BAE
;
Eun Hee KWON
;
Woon Bo HEO
;
Se Hyun SHIN
;
Jang Soo SUH
Author Information
1. Department of Laboratory Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. suhjs@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Multi-drug resistance;
Acute leukemia;
P-glycoprotein;
mdr1 gene;
Daunorubicin efflux
- MeSH:
Bone Marrow;
Daunorubicin;
Drug Resistance, Multiple*;
Drug Therapy;
Flow Cytometry;
Genes, MDR;
Humans;
Leukemia*;
Leukemia, Myeloid, Acute;
P-Glycoprotein;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Recurrence;
RNA, Messenger
- From:The Korean Journal of Laboratory Medicine
2003;23(3):143-150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The expression of multi-drug resistance (MDR) in acute leukemia was known to decrease the outcome of chemotherapy and to increase the rate of relapse. Of the mechanism of MDR, the most well known is P-glycoprotein (P-gp) encoded by the mdr1 gene. There are MDR genes, P-gp tests and drug efflux function tests for the clinical measurement of MDR. To assess the clinical usefulness and MDR expression status in acute leukemia, MDR tests were performed. METHODS: MDR expression was assessed by MDR1 mRNA RT-PCR and flow cytometry measuring P-gp and daunorubicin (DNR) efflux in 77 patients with newly diagnosed acute leukemia (AL) including 48 acute myeloid leukemia (AML), 16 acute lymphoblastic leukemia (ALL) and 13 acute mixed-lineage leukemia (AMLL). The CD34 surface-marker study was also done by flow cytometry. The result of chemotherapy was evaluated by the percentage of remnant bone marrow (BM) blasts. RESULTS: The positivity of MDR1 mRNA was 57.1% (44/77) in AL, 61.5% (8/13) in AMLL, 60.4% (29/48) in AML, and 43.8% (7/16) in ALL. The positivity of P-gp expression was 36.5% (27/74) in AL and 100% in AML. The positivity of the DNR efflux test was 30.1% (22/73) in AL, 40.0% (18/45) in AML, 23.1% (3/13) in AMLL, and 6.7% (1/15) in ALL. There was a significant correlation between MDR1 mRNA and P-gp expression and between MDR1 mRNA and CD34 expression in AML. There was a significant correlation between the percentages of residual blast cells in BM and P-gp expression (P=0.039, r=0.312). CONCLUSIONS: It can be clinically useful to perform the mdr1 gene and P-gp test simultaneously both in newly diagnosed acute leukemia patients. The effectiveness of tests for MDR can be helpful to predict the outcome of chemotherapy.
